Operator
Good afternoon, and welcome to the REGENXBIO First Quarter 2021 Earnings Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded. I would now like to turn the call over to Mr. Patrick Christmas, Chief Legal Officer of REGENXBIO. You may begin.
Patrick J. Christmas II, J.D.
Chief Legal Officer
Good afternoon, and thank you for joining us. With us today are Ken Mills, REGENXBIO s President and Chief Executive Officer; and Dr. Steve Pakola, our Chief Medical Officer. Earlier this afternoon, REGENXBIO released financial and operating results for the first quarter ended March 31, 2021. The press release reporting our financial results is available on our website at www.regenxbio.com. Today s conference call will include forward-looking statements regarding our financial outlook in addition to regulatory and product development plans. These forward-looking statements are subject to risks and uncertainties that may cause actual results
A complete guide to Moderna stock A complete guide to Moderna stock
Oliver Brett May 6, 2021 10:53 AM
Moderna has risen rapidly through the ranks of “big pharma” companies after winning multiple contracts to produce Covid-19 vaccines for large sections of the world’s populations. But is it profitable and what scope does it have for growth? Read our guide for the full lowdown. Share:
What does Moderna do?
Moderna is a pharmaceutical and biotechnology company based in the United States with headquarters in Cambridge, Massachusetts, the city where the world-renowned Harvard University is situated. Moderna focuses on drug discovery, drug development, and vaccine technologies and was founded in 2010.
Operator
Good day, and thank you for standing by. Welcome to the Sangamo First Quarter 2021 Teleconference Call. [Operator Instructions].
I would now like to hand the conference over to your speaker today, Aron Feingold, Head of Corporate Communications. Please go ahead.
Aron Feingold
Head of Corporate Communications
Good afternoon, and thank you for joining us today. With me this afternoon on this call are several members of the Sangamo executive leadership team, including Sandy Macrae, Chief Executive Officer; Mark McClung, Chief Business Officer; Jason Fontenot, Chief Scientific Officer; Rob Schott, Head of Development; and Bettina Cockroft, Chief Medical Officer. Slides from our corporate presentation can be found on our website, sangamo.com, under the Investors and Media section on the Events and Presentations page.
Operator
Good day and thank you for standing by. Welcome to the Q1 2021 Editas Medicine Earnings Conference Call. At this time, all participants are in a listen-only mode. [Operator Instructions]
I would now like to hand the conference over to your first speaker today, Ron Moldaver, Investor Relations. Please go ahead.
Ron Moldaver
Investor Relations
Thank you, Julian. Good morning, everyone, and welcome to our first quarter 2021 conference call. Earlier this morning, we issued a press release providing our financial results and corporate updates for the first quarter of 2021. A replay of today s call will be available on the Investors section of our website approximately 2 hours after its completion. After our prepared remarks, we will open the call for Q&A.